Biologics in Plaque Psoriasis

Biologics require formulary management strategies to manage expenditures, due to a lack of or delay in biosimilar development and market approval. A CADTH Integrated Technology Review on biologics for plaque psoriasis (PsO) indicated that although several old-generation biologics used to treat PsO have lost exclusivity, they represent a significant portion of expenditures. These biologics often predate pan-Canadian Pharmaceutical Alliance (pCPA) agreements, whereas new-generation biologics, which have demonstrated more favourable outcomes versus old-generation biologics in head-to-head trials, have negotiated prices under pCPA agreements. Notably, some new-generation biologics will also soon lose data protection, which will further increase this opportunity cost.

It is prudent that decision-makers continue to review the place in therapy of biologics for PsO. This Streamlined Drug Class Review was initiated to assess the clinical and economic value of biologics in the context of current evidence standards in PsO and to modernize their reimbursement recommendations.